IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04372433 |
Recruitment Status :
Recruiting
First Posted : May 4, 2020
Last Update Posted : March 15, 2024
|
Sponsor:
Immune-Onc Therapeutics
Collaborator:
California Institute for Regenerative Medicine (CIRM)
Information provided by (Responsible Party):
Immune-Onc Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | January 31, 2026 |
Estimated Study Completion Date : | January 31, 2027 |